Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Prepublished online as a Blood First Edition Paper on April 24, 2003; DOI 10.1182/blood-2003-01-0334.

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
2003-01-0334v1
102/4/1155    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xiong, J.-P.
Right arrow Articles by Arnaout, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiong, J.-P.
Right arrow Articles by Arnaout, M. A.
Related Collections
Right arrow Perspectives
Right arrow Cell Adhesion and Motility
Right arrow Signal Transduction
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 15 August 2003, Vol. 102, No. 4, pp. 1155-1159

PERSPECTIVES

New insights into the structural basis of integrin activation

Jian-Ping Xiong, Thilo Stehle, Simon L. Goodman, and M. Amin Arnaout

From the Renal Unit, Leukocyte Biology and Inflammation Program, Structural Biology Program, Massachusetts General Hospital, and Harvard Medical School, Charlestown, MA; Laboratory of Developmental Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA; and Department of Oncology Research, Merck KGaA, Darmstadt, Germany.

Abstract

Integrins are cell adhesion receptors that communicate biochemical and mechanical signals in a bidirectional manner across the plasma membrane and thus influence most cellular functions. Intracellular signals switch integrins into a ligand-competent state as a result of elicited conformational changes in the integrin ectodomain. Binding of extracellular ligands induces, in turn, structural changes that convey distinct signals to the cell interior. The structural basis of this bidirectional signaling has been the focus of intensive study for the past 3 decades. In this perspective, we develop a new hypothesis for integrin activation based on recent crystallographic, electron microscopic, and biochemical studies.

Introduction

Integrins are {alpha}{beta} heterodimeric cell surface receptors, about 24 nm long, that assemble into a ligand-binding "head" sitting on 2 membrane-spanning legs.1,2 Integrins require activation to bind physiologic ligands (for a review, see Hynes3). Activation is normally induced from within the cell through the cytoplasmic and transmembrane (TM) regions ("inside-out" activation)4 and can be mimicked by deleting the TM or cytoplasmic segments (for a review, see Arnaout5; Figure 1). In this case, activating intracellular signals transition the integrin through conformational changes to the active state.6 This process is fast (< 1 second), temperature dependent,7 and reversible.8,9 Activation is also associated with rapid (within seconds) changes in the lateral mobility of integrins in the plasma membrane that act in concert with affinity modulation to regulate cell adhesion.10,11 Binding energetics suggest that once bound to a physiologic ligand, dissociation is energetically expensive.7 High-affinity ligand-mimic peptides,12,13 Mn2+,14 certain monoclonal antibodies (mAbs), and gain-of-function mutations in the extracellular segment (for a review, see Arnaout5) can mimic inside-out activation (outside-in activation; Figure 1), reflecting a dynamic link between the integrin's head and tails. A classic example of this conformational coupling is seen in electron microscopic images of an activating mAb (LIBS2) to the membrane proximal integrin leg, which causes physiologic ligand binding to the head some 16 nm away.15 The atomic basis for this bidirectional and reversible allosteric activation has remained enigmatic. New crystallographic, electron microscopic, and biochemical studies that are providing new potential solutions to this problem are reviewed here.



View larger version (15K):
[in this window]
[in a new window]
  		Figure 1.. A schematic of inside-out or outside-in integrin activation. Opening of the head or legs/feet opens the other end of the integrin perhaps through an intermediate state(s). The ligand-occupied active integrin causes further conformational changes resulting in clustering and cell signaling. Dotted line depicts the plasma membrane.

 

Surprising findings in the crystal structure of integrin {alpha}V{beta}3

It was a big surprise when the crystal structure of the extracellular (ie, lacking the transmembrane and cytoplasmic tails) segment of integrin {alpha}V{beta}3 was found to be V-shaped16 (Figure 2), rather than being linear and extended as depicted in electron microscopic images. The 4-domain {alpha}V subunit and the 8-domain {beta}3 subunit are acutely bent some 135 degrees from the linear, with the bending found in the legs, between the thigh and calf-1 domains of {alpha}V and about the second and third epidermal growth factor (EGF) repeats of {beta}3 (at the integrin {alpha} and {beta} knees, respectively; Figure 2). One interpretation of the severe bending of the integrin is that it is a crystal artifact.17 Another interpretation is that the bent conformation represents a constitutive and regulatable form of the integrin.16 This view is supported by electron microscopic images of negatively stained native {alpha}IIb{beta}3 on the cell surface,2 and more recently by electron microscopic data showing that extracellular {alpha}V{beta}3 is bent in solution.18 A second surprising finding in the structure was the striking resemblance in the tertiary and quaternary arrangements of the integrin head to G-proteins; the integrin head is formed by a {beta} propeller from {alpha}V and a VWFA Rossmann fold ({beta}A) from {beta}3 ({beta}A is similar to the ligand-binding {alpha}A- or {alpha}I domain found earlier in the {alpha} subunits of 9 integrins19,20). The integrin's {beta}A and propeller domains were found to be the structural equivalents of the nucleotide binding (G{alpha}) and propeller (G{beta}) domains of G-proteins. This striking resemblance suggested that integrin activation might, like G-proteins, also involve tertiary and quaternary changes in the head region. The third surprising finding was that the metal ion-dependent ligand-binding site (MIDAS) of the {beta}A domain was unoccupied by a metal ion due to an invariant glutamate side chain that partially occupies this site; instead, a metal ion was found at an adjacent site to MIDAS (ADMIDAS), linking the {alpha}1 and {alpha}7 helices of {beta}A. The lack of a MIDAS cation and the presence of an ADMIDAS cation in {beta}A contrasts with the situation in the integrin-{alpha}A domain, which exists in inactive "closed" and liganded "open" conformations,20,21 both with a metal ion at MIDAS but lacking the ADMIDAS coordination site.



View larger version (45K):
[in this window]
[in a new window]
  		Figure 2.. Ribbon diagram of the structure of the unliganded extracellular {alpha}V{beta}3. The protein is bent at a flexible region (the genu, arrow; A). When extended at the genu,16 the structure assumes the more familiar shape seen previously by electron microscopy (B). The 12 domains are labeled. The PSI, EGF1, and EGF2 domains are not visible (indicated in gray); the tracing shown for PSI is approximate and the translated EGF3 and EGF4 domains have been used to show the approximate location of EGF1 and EGF2. The 4 metal ions (orange spheres) at the bottom of the propeller, the metal ion at the genu (orange), and the ADMIDAS ion (magenta) are shown. The dotted line in calf-2 represents the disordered loop containing the proteolytic cleavage site. A short dotted line also connects PSI and the hybrid domains, visible in panel B. The "n" and "c" indicate the amino and carboxyl terminus, respectively. Reprinted from Arnaout et al58 with permission.

 

A switchblade model of integrin activation

The discovery of the bent integrin conformation together with previous electron microscopic images of an extended form suggested that, as in the case of {alpha}A, interconversion between these 2 conformations may have important functional consequences.16 In one model, it was proposed that in response to an inside-out signal, integrins extend at the knees, snapping from the bent structure that is inactive to the straight active conformation, like the opening of a pocket knife (switchblade or jack-knife model).18 Inactivity of the bent form was inferred from the fact that it was produced in the presence of the generally inhibitory cation Ca2+ and from predictions that the head of the integrin would face down toward the membrane in this conformation and is therefore unable to bind ligands.22 Evidence has been gathered in support of the 2-state "switchblade" model. First, artificially constrained recombinant integrins, where a disulfide bridge clasps the membrane-proximal {alpha} and {beta} legs together, bind immobilized ligand only when unclasped23; in the bent crystal structure, the {alpha} and {beta} legs are very close together, potentially hampering access to activating mAbs.22 Second, estimation of the Stokes radius of extracellular {alpha}V{beta}3 by molecular sieve chromatography revealed that in buffers containing Ca2+ or Mn2+, the Stokes radius is 5.7 nm and 6.0 nm, respectively, and the respective electron microscopic images revealed a bent conformation except for a minority of the Mn2+-bound molecules (~20%) that were extended. When a cyclic RGDfV (Arg-Gly-Asp-[D]Phe-Val) pentapeptide was added in Ca2+ or Mn2+ buffers, the Stokes radius shifted to about 6.4 nm and the vast majority of the molecules were now seen extended by electron microscopy. Third, a double mutation designed to hold the head against the legs via a cysteine bridge resulted in an inactive integrin unless the receptor was reduced with dithiothreitol (DTT).18

Crystal structures of {alpha}V{beta}3 in Mn2+ and in complex with RGD

In the meantime, we determined 2 additional crystal structures of extracellular {alpha}V{beta}3. One was generated by cocrystallization in the presence of 5 mM Mn2+,24 and the second after allowing the high-affinity ligand mimetic cyclic (RGDf[N-Me]V) to diffuse into existing {alpha}V{beta}3 crystals grown in the presence of Mn2+.24 The former structure was virtually identical to that generated earlier in the presence of Ca2+, including the lack of a MIDAS cation in {beta}A and the presence of a cation-occupied ADMIDAS. In the {alpha}V{beta}3-RGD structure, RGD occupies a shallow crevice between the propeller and {beta}A domains in the integrin head (Figure 3A), with the arginine and aspartic acid residues exclusively contacting the propeller and {beta}A domains, respectively. RGD binding is associated with tertiary changes, mostly affecting {beta}A, and small quaternary changes in the propeller/{beta}A interface. The tertiary changes reshape the 3 loops surrounding the {beta}A MIDAS (Figure 3B). These changes are triggered by a similar movement of the N-terminal {alpha}1 helix to that seen when {alpha}A is liganded (compare panels B and C in Figure 3). In {beta}A, this movement is accompanied by 2 major changes. (1) Due to its shift toward the RGD ligand, the coordination of ADMIDAS cation changes; the F-{alpha}7 loop flips so that this cation no longer interacts with the top of the C-terminal {alpha}7 helix, thus severing the ionic bond between {alpha}1 and {alpha}7 helices. (2) The invariant glutamic acid side chain from loop 2, which prevents occupation of MIDAS in unliganded {alpha}V{beta}3, changes its position to coordinate a third metal ion at a novel ligand-associated metal ion-binding site (LIMBS). Displacement of this glutamate now allows for occupation of MIDAS with a metal ion, that is, the {beta}A MIDAS only binds a metal ion in the presence of the high-affinity ligand mimic. This contrasts with the situation in {alpha}Awhere MIDAS is metal bound even in the inactive "closed" conformation. Ligand-dependent occupation of the {beta}A MIDAS is consistent with recent biochemical analysis of 45Ca binding to integrin {alpha}4{beta}1, which identified a moderate affinity (median effective dose [ED50] about 50-100 µM) site seen only when a high-affinity ligand is present.25 In isolated {alpha}A, movement of the {alpha}1 helix reorients the metal ion at MIDAS and the flip in the F-{alpha}7 loop leads to a major 10-Å downward movement of the {alpha}7 helix (Figure 3C), not seen in the liganded {beta}Astructure (Figure 3B). The functional end result, however, is essentially the same; the metal ion at MIDAS can now be ligated by an acidic residue from ligand. Similar changes in metal coordination, associated with the conversion of the molecule from the inactive to the active state, are found in G-proteins; these are also linked to large tertiary changes in 2 switch regions.26 But these changes are not accompanied by movement of the C-terminal helix, as in {beta}A, indicating that this movement is not essential for switching of the homologous G-proteins to the active state.



View larger version (32K):
[in this window]
[in a new window]
  		Figure 3.. The ligand binding site of {alpha}V{beta}3 and the unliganded and liganded conformations of {beta}A and {alpha}A domains. (A) Surface representation of the RGD ligand-binding site in the head section of {alpha}V{beta}3. The ligand arginine-binding pocket is located in the {alpha}V propeller (blue) and the aspartic acid–binding pocket in {beta}A (red). The ligand peptide is shown as a ball-and-stick model (carbons are shown in green, amides in blue, and oxygens in red). (B) Superposition of the {beta}3A domain in the unliganded and liganded conformations. Ligand is in yellow. The 3 metal ions present in the liganded form (LIMBS, MIDAS, and ADMIDAS) are shown in gray, cyan, and magenta, respectively. (C) Superposition of CD11b A domain in the "closed" and "open" forms. Ligand is in yellow. The MIDAS cation is in cyan. In both panels B and C, the C-terminal {beta}{alpha}{beta}{alpha}{beta}{alpha} structures are highlighted in color (blue for unliganded and red for liganded), and the remaining parts of the molecules are in gray. The C-terminal {alpha} helix ({alpha}7) is boxed. In panel B, superpositions are generated for the whole molecule with TOP,59 whereas in panel C, superpositions are based on the central {beta} sheet only.

 

As suggested,24 the structural changes seen in the {alpha}V{beta}3-RGD complex may correspond to outside-in activation of membrane-bound12,13 or recombinant extracellular integrins27 induced by short RGD ligand mimetic peptides. These induce binding of physiologic ligands in the integrin head and expression of neoepitopes in the legs.15,28,29 Biochemical studies using mAbs and limited proteolysis identified the {alpha}1 helix of {beta}A and the preceding and adjacent ligand-specificity loops,25,30-34 the propeller/thigh and propeller/{beta}A interfaces,35,36 and the disordered PSI/hybrid/EGF1 interface35,37 as regions that become exposed only in the active state (for a review, see Arnaout5). The congruence of the activation-sensitive regions as defined biochemically in integrins activated from "inside-out" and crystallographically by comparing the structures of the unliganded and liganded {alpha}V{beta}3 suggests that the tertiary changes induced by RGD in our crystals mirror those induced by inside-out activation. The switchblade model argues based on comparisons of negatively stained electron microscopic images of extracellular {alpha}V{beta}3,18 that in addition to these changes, there is a downward movement of the C-terminal helix of {beta}A in the liganded structure, which is prevented by crystal contacts.

The missing link: the integrin "ankles" or TM segments

The impact of the TM segment on protein movements leading to activation is yet to be determined, and it is in this context that the switchblade model faces some challenges. In a recent study, the 20-Å cryoelectron microscopic structure of the native inactive {alpha}IIb{beta}3 was described.38 Although the electron microscopic images are not consistent with the bent structure of the crystallized protein, they do show a rather collapsed structure that is perhaps more similar to, and retains features of, the crystallized protein. In the "best fit" model, the membrane-proximal calf-2 domain is almost parallel to the plasma membrane; thus the ligand-binding face is facing away from the membrane and able to potentially engage ligands. In this structure, movements at additional "joints" besides the knees are necessary for the integrin to snap to the extended linear form.38 Second, inspection of detailed mAb epitope maps of active and inactive {alpha}IIb{beta}3 on platelet membranes led to the conclusion that both states can assume a compact form consistent with the bent conformation, that is, the structure does not need to linearize to become active.39 The inactivating effect of "freezing" an integrin in its bent unliganded state by artificial disufides linking the head and legs, which supports the switchblade model, may not be that surprising; this modification probably blocks the tertiary and quaternary changes needed for activation that occur even in protein crystals. It may thus well be that extension at the knees is not a necessary feature of activation per se, but a postbinding event linked to outside-in signaling. Activation and extension can be dissociated; extracellular {alpha}5{beta}1 tied at its legs assumed a straight conformation by electron microscopy yet was inactive.23 Also, the binding of cyclic peptide ligand mimics to {alpha}IIb{beta}3 in intact platelets triggers different conformational changes in the receptor, as reflected by expression of different LIBS epitopes,40 suggesting that various ligands initiate distinct functional consequences within the receptor. Varying degrees of extension at the knees may provide the structural basis for these findings.

Inside-out activation of the integrin heterodimer: the "deadbolt" model

If extension at the knees is a postbinding "outside-in" signaling event, and the bent structure can be activated (stabilized) by high-affinity RGD, then how is inside-out activation triggered? The answer is currently unknown, but the bent crystal structure may offer yet another intriguing clue. The F/{alpha}7 loop is the region in {beta}A that undergoes the most dramatic conformational change on RGD binding (Figure 3B). This loop contacts the CD loop of the {beta}TD in unliganded {alpha}V{beta}3 (Figure 4A-B) and this contact is lost in the liganded structure. The contact region covers a very small surface area (~64 Å2) in unliganded {alpha}V{beta}3 and the {beta}TD loop has high temperature factors. Thus this contact does not contribute much stabilizing energy to the bent form in the crystal structure. The same side of the {beta}TD ({alpha}1/A loop) also makes a small contact (~270 Å2 of surface area) of a mixed nature with the hybrid domain that may stabilize the {beta}TD/{beta}A contact. The close proximity of the {beta}TD and {beta}A domains may produce a more substantial contact following minor rearrangement of the {alpha} and {beta} subunits and their domain interfaces in the native membrane-bound structure. In the structurally related {alpha}A domains, integrin affinity can be regulated allosterically by modulating the structure of the F/{alpha}7 region.41,42 In addition, lovastatin, a drug that binds at the lower part of the F/{alpha}7 interface (Figure 4C), has been shown to lock the {alpha}A domain from integrin CD11a in the inactive state, by preventing the tertiary changes in its C-terminal {alpha}7 helix and preceding F/{alpha}7 loop needed for activation.43 We suggest that the elongated CD loop of the {beta}TD may serve a similar function, acting as a regulatable "deadbolt" that locks {beta}A in the inactive state in the native structure. In the latter state, the deadbolt would be more firmly engaged than observed in the crystallized protein, thus preventing the flip of the F/{alpha}7 loop required for the activating movement of the {alpha}1 helix. Inside-out activation transmitted through the integrin cytoplasmic tails4,44 may lead through pistonlike, seesaw,4 sliding,45 or rotational46 movements of the TM helices to unlocking of the adjacent {beta}TD "deadbolt." The deadbolt would slide away from {beta}A, rendering it ligand competent. If true, one would not expect to see an extensive contact in an active integrin (or one where the cytoplasmic tails and TM segments are removed47 as in the crystallized protein) because the deadbolt is not fully inserted into its {beta}A "lock." Perhaps this is why the CD loop of {beta}TD has high temperature factors; some mobility might help it re-engage the {beta}A domain to reversibly inactivate the integrin, a motion of only 0.3 nm. A model, where the {beta}TD and the {beta}A domains interact over a couple of angstroms via the {beta}TD "deadbolt" to maintain the inactive state, may act as the key that allows intracellular or membrane proximal signals to effect subjectively long range activation at the {beta}A domain. A particularly attractive feature of this deadbolt model for reversible inside-out activation in a membrane-bound integrin is that this mechanism seems more efficient than evoking a snap opening of the molecule into the linear form. It also incorporates the unique and hitherto unexplained features of the {beta}A domain; the ADMIDAS cation is situated right at the top of the F/{alpha}7 loop and could participate in stabilizing this loop through an ionic bridge to the {alpha}1 helix in the inactive native state. The deadbolt model does not exclude a subsequent physiologic ligand-induced switchblade movement that could be key to outside-in signaling.



View larger version (69K):
[in this window]
[in a new window]
  		Figure 4.. The deadbolt model of inside-out integrin activation. (A) Surface representation of unliganded {alpha}V{beta}3 in which the {beta}TD (blue), hybrid (yellow), and {beta}A (red) domains are colored and the propeller (P), thigh (T), calf-1 and 2 (C1, C2), and EGF4 (E4) are labeled. The cations at ADMIDAS (magenta) and blade 6 (orange) are visible in this view. (B) Ribbon diagram showing the 2 {beta}TD loops ({star}, blue) that contact {beta}A (red) and the hybrid (yellow) domains. The long CD loop of the {beta}TD contacts the top of the activation-sensitive F/{alpha}7 of {beta}A (colored in green). The ADMIDAS cation links this loop to the top of the {alpha}1 helix in the unliganded state. Parts of the propeller (cyan), hybrid (yellow), and EGF4 (white) are shown. (C) Ribbon diagram of the inactive form of {alpha}A from integrin CD11a in complex with the allosteric inhibitor lovastatin (blue) showing the position of this drug in relation to the F/{alpha}7 region (colored in green). The MIDAS ion is in cyan. There is no ADMIDAS in this or other known {alpha}A domains.

 

Many of the existing data supportive of the switchblade model on inside-out activation may in fact be more consistent with the deadbolt model. A part of the {beta}TD/hybrid interface is exposed when {alpha}IIb{beta}3 is activated; Asp393, a contact residue at the {beta}TD/hybrid interface becomes accessible to Asp-N protease only in the active state.35 Conformational changes at the {beta}TD/hybrid interface may act in the bent structure to unlock the deadbolt. Second, epitopes of several activating mAbs map at or adjacent to the {beta}TD/{beta}A interface. For example, the activating anti-{beta}1 mAb JB1B involves the {beta}TD CD loop of the deadbolt48; the epitopes of the activating anti-{beta}1 mAbs HUTS-4, HUTS-7, HUTS-21,49 and 15/750 involve the adjacent {beta}TD contact with the hybrid domain. The activating anti-{beta}2 mAb, KIM185, maps to EGF4 and the N-terminus of the {beta}TD.51 The {beta}TD of {beta}3 contains several epitopes for activating mAbs, including those for LIBS2, LIBS3, and LIBS6.15 In our model, these mAbs would also act by unlocking the deadbolt without necessarily straightening the integrin. Third, 4 naturally occurring activating mutations are now known in {alpha}IIb{beta}3: Thr562Asn52 and Cys560Phe53 (both in EGF3); and Gly579Ser53 and Cys598Tyr54 (both in EGF4). Thr562 is the last residue in EGF3; its replacement with asparagine permits an aberrant glycanation at this site, which may disrupt the EGF3/4 interface and thence the {beta}TD/{beta}A interface. Cys560 participates in the interdomain disulfide bridge linking EGF3 and 4; loss of this cysteine will likely have an equivalent structural effect to that caused by Thr562Asn. Cys598 forms an intradomain disulfide bond, linking the major and minor strands of EGF4; interruption of this linkage may also loosen/disrupt the {beta}TD/{beta}A interface. Fourth, deletion of the transmembrane/cytoplasmic segments activates integrins (for a review, see Humphries et al55). This is expected to loosen the grip of the deadbolt, as seen in the tailless structure of {alpha}V{beta}3. Finally, the rare activating anti-{alpha}IIb mAb PMI-1 binds to calf-2,56,57 in a region adjacent to the {beta}TD and could also function in part by unlocking the deadbolt.

Because integrins are emerging therapeutic targets in many human pathologies, the ability to recognize and to target the appropriate molecular form, and to ensure this does not trigger a potentially harmful activating switch, has become a central focus of therapy. The deadbolt model predicts a defined region in the native integrin that normally locks it in a default inactive state. Drugs mimicking the deadbolt mechanism may achieve the long-sought goal of inactivating an integrin by preventing the activation switch altogether, thus avoiding potentially serious side effects.


   Footnotes
 
Submitted February 19, 2003; accepted April 9, 2003.

Footnotes

Prepublished online as Blood First Edition Paper, April 24, 2003; DOI 10.1182/blood-2003-01-0334.

Supported by grants from the National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Disease, National Institute of Allergy and Infectious Diseases, and National Heart, Lung and Blood Institute).

Reprints: M. Amin Arnaout, Renal Unit, Leukocyte Biology and Inflammation Program, Structural Biology Program, Massachusetts General Hospital, and Harvard Medical School, 149 13th St, Charlestown, MA 02129; e-mail: arnaout{at}receptor.mgh.harvard.edu.

References

  1. Nermut MV, Green NM, Eason P, Yamada SS, Yamada KM. Electron microscopy and structural model of human fibronectin receptor. EMBO J. 1988;7: 4093-4099.[Medline] [Order article via Infotrieve]

  2. Erb EM, Tangemann K, Bohrmann B, Muller B, Engel J. Integrin alphaIIb beta3 reconstituted into lipid bilayers is nonclustered in its activated state but clusters after fibrinogen binding. Biochemistry. 1997;36: 7395-7402.[CrossRef][Medline] [Order article via Infotrieve]

  3. Hynes RO. Integrins: versatility, modulation and signaling in cell adhesion. Cell. 1992;69: 11-26.[CrossRef][Medline] [Order article via Infotrieve]

  4. Hughes PE, Diaz-Gonzalez F, Leong L, et al. Breaking the integrin binge. J Biol Chem. 1996;271: 6571-6574.[Abstract/Free Full Text]

  5. Arnaout MA. Integrin structure: new twists and turns in dynamic cell adhesion. Immunol Rev. 2002;186: 125-140.[CrossRef][Medline] [Order article via Infotrieve]

  6. Garcia AJ, Takagi J, Boettiger D. Two-stage activation for alpha5beta1 integrin binding to surface-adsorbed fibronectin. J Biol Chem. 1998;273: 34710-34715.[Abstract/Free Full Text]

  7. Cai TQ, Wright SD. Energetics of leukocyte integrin activation. J Biol Chem. 1995;270: 14358-14365.[Abstract/Free Full Text]

  8. Hantgan RR, Paumi C, Rocco M, Weisel JW. Effects of ligand-mimetic peptides Arg-Gly-Asp-X (X = Phe, Trp, Ser) on alphaIIbbeta3 integrin conformation and oligomerization. Biochemistry. 1999;38: 14461-14474.[CrossRef][Medline] [Order article via Infotrieve]

  9. Cai TQ, Law SK, Zhao HR, Wright SD. Reversible inactivation of purified leukocyte integrin CR3 (CD11b/CD18, alpham beta2) by removal of divalent cations from a cryptic site. Cell Adhes Commun. 1995;3: 399-406.[Medline] [Order article via Infotrieve]

  10. Hato T, Pampori N, Shattil SJ. Complementary roles for receptor clustering and conformational change in the adhesive and signaling functions of integrin alphaIIb beta3. J Cell Biol. 1998;141: 1685-1695.[Abstract/Free Full Text]

  11. Constantin G, Majeed M, Giagulli C, et al. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity. 2000;13: 759-769.[CrossRef][Medline] [Order article via Infotrieve]

  12. Du X, Plow EF, Frelinger AL, O'Toole TE, Loftus JC, Ginsberg MH. Ligands "activate" integrin {alpha} IIb{beta}3 (platelet GPIIb-IIIa). Cell. 1991;65: 409-416.[CrossRef][Medline] [Order article via Infotrieve]

  13. Mazurov AV, Khaspekova SG, Byzova TV, et al. Stimulation of platelet glycoprotein IIb-IIIa (alphaIIb beta3-integrin) functional activity by a monoclonal antibody to the N-terminal region of glycoprotein IIIa. FEBS Lett. 1996;391: 84-88.[CrossRef][Medline] [Order article via Infotrieve]

  14. Smith JW, Piotrowicz RS, Mathis D. A mechanism for divalent cation regulation of beta3-integrins. J Biol Chem. 1994;269: 960-967.[Abstract/Free Full Text]

  15. Du X, Gu M, Weisel JW, et al. Long range propagation of conformational changes in integrin alphaIIb beta3. J Biol Chem. 1993;268: 23087-23092.[Abstract/Free Full Text]

  16. Xiong JP, Stehle T, Diefenbach B, et al. Crystal structure of the extracellular segment of integrin alphaV beta3. Science. 2001;294: 339-345.[Abstract/Free Full Text]

  17. Liddington RC, Ginsberg MH. Integrin activation takes shape. J Cell Biol. 2002;158: 833-839.[Abstract/Free Full Text]

  18. Takagi J, Petre BM, Walz T, Springer TA. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 2002;110: 599-511.[CrossRef][Medline] [Order article via Infotrieve]

  19. Michishita M, Videm V, Arnaout MA. A novel divalent cation-binding site in the A domain of the {beta}2 integrin CR3 (CD11b/CD18) is essential for ligand binding. Cell. 1993;72: 857-867.[CrossRef][Medline] [Order article via Infotrieve]

  20. Lee J-O, Rieu P, Arnaout MA, Liddington R. Crystal Structure of the A-domain from the {alpha}-subunit of {beta}2 integrin complement receptor type 3 (CR3, CD11b/CD18). Cell. 1995;80: 631-638.[CrossRef][Medline] [Order article via Infotrieve]

  21. Lee J-O, Anne-Bankston L, Arnaout MA, Liddington RC. Two conformations of the integrin A-domain (I-domain): a pathway for activation? Structure. 1995;3: 1333-1340.[Medline] [Order article via Infotrieve]

  22. Beglova N, Blacklow SC, Takagi J, Springer TA. Cysteine-rich module structure reveals a fulcrum for integrin rearrangement upon activation. Nat Struct Biol. 2002;9: 282-287.[CrossRef][Medline] [Order article via Infotrieve]

  23. Takagi J, Erickson HP, Springer TA. C-terminal opening mimics `inside-out' activation of integrin alpha5beta1. Nat Struct Biol. 2001;8: 412-416.[CrossRef][Medline] [Order article via Infotrieve]

  24. Xiong JP, Stehle T, Zhang R, et al. Crystal structure of the extracellular segment of integrin alphaV beta3 in complex with an Arg-Gly-Asp ligand. Science. 2002;296: 151-155.[Abstract/Free Full Text]

  25. Chen LL, Whitty A, Scott D, et al. Evidence that ligand and metal ion binding to integrin alpha4 beta1 are regulated through a coupled equilibrium. J Biol Chem. 2001;276: 36520-36529.[Abstract/Free Full Text]

  26. Wall MA, Coleman DE, Lee E, et al. The structure of the G protein heterotrimer Gi alpha 1 beta 1 gamma 2. Cell. 1995;83: 1047-1058.[CrossRef][Medline] [Order article via Infotrieve]

  27. Legler DF, Wiedle G, Ross FP, Imhof BA. Super-activation of integrin alphavbeta3 by low antagonist concentrations. J Cell Sci. 2001;114: 1545-1553.[Abstract]

  28. Tsuchida J, Ueki S, Takada Y, Saito Y, Takagi J. The `ligand-induced conformational change' of alpha 5 beta 1 integrin. Relocation of alpha5 subunit to uncover the beta1 stalk region. J Cell Sci. 1998;111(pt 12):1759-1766.

  29. Pelletier AJ, Kunicki T, Ruggeri ZM, Quaranta V. The activation state of the integrin alpha IIb beta 3 affects outside-in signals leading to cell spreading and focal adhesion kinase phosphorylation. J Biol Chem. 1995;270: 18133-18140.[Abstract/Free Full Text]

  30. Andrieux A, Rabiet MJ, Chapel A, Concord E, Marguerie G. A highly conserved sequence of the Arg-Gly-Asp-binding domain of the integrin beta3 subunit is sensitive to stimulation. J Biol Chem. 1991;266: 14202-14207.[Abstract/Free Full Text]

  31. Kouns WC, Steiner B, Kunicki TJ, et al. Activation of the fibrinogen binding site on platelets isolated from a patient with the Strasbourg I variant of Glanzmann's thrombasthenia. Blood. 1994;84: 1108-1115.[Abstract/Free Full Text]

  32. Calvete JJ. On the structure and function of platelet integrin alphaIIb beta3, the fibrinogen receptor. Proc Soc Exp Biol Med. 1995;208: 346-360.[Abstract]

  33. Lu C, Shimaoka M, Zang Q, Takagi J, Springer TA. Locking in alternate conformations of the integrin alphaL beta2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc Natl Acad Sci U S A. 2001;98: 2393-2398.[Abstract/Free Full Text]

  34. Mould AP, Askari JA, Barton S, et al. Integrin activation involves a conformational change in the alpha 1 helix of the beta subunit A-domain. J Biol Chem. 2002;277: 19800-19805.[Abstract/Free Full Text]

  35. Yan B, Hu DD, Knowles SK, Smith JW. Probing chemical and conformational differences in the resting and active conformers of platelet integrin alphaIIb beta3. J Biol Chem. 2000;275: 7249-7260.[Abstract/Free Full Text]

  36. Sims PJ, Ginsberg MH, Plow EF, Shattil SJ. Effect of platelet activation on the conformation of the plasma membrane glycoprotein IIb-IIIa complex. J Biol Chem. 1991;266: 7345-7352.[Abstract/Free Full Text]

  37. Valentin N, Visentin GP, Newman PJ. Involvement of the cysteine-rich domain of glycoprotein IIIa in the expression of the human platelet alloantigen, PlA1: evidence for heterogeneity in the humoral response. Blood. 1995;85: 3028-3033.[Abstract/Free Full Text]

  38. Adair BD, Yeager M. Three-dimensional model of the human platelet integrin alpha IIbbeta 3 based on electron cryomicroscopy and x-ray crystallography. Proc Natl Acad Sci U S A. 2002;99: 14059-14064.[Abstract/Free Full Text]

  39. Calzada MJ, Alvarez MV, Gonzalez-Rodriguez J. Agonist-specific structural rearrangements of integrin alpha IIbbeta 3. Confirmation of the bent conformation in platelets at rest and after activation. J Biol Chem. 2002;277: 39899-39908.[Abstract/Free Full Text]

  40. Cierniewski CS, Byzova T, Papierak M, et al. Peptide ligands can bind to distinct sites in integrin alphaIIbbeta3 and elicit different functional responses. J Biol Chem. 1999;274: 16923-16932.[Abstract/Free Full Text]

  41. Huth JR, Olejniczak ET, Mendoza R, et al. NMR and mutagenesis evidence for an I domain allosteric site that regulates lymphocyte function-associated antigen 1 ligand binding. Proc Natl Acad Sci U S A. 2000;97: 5231-5236.[Abstract/Free Full Text]

  42. Xiong JP, Li R, Essafi M, Stehle T, Arnaout MA. An isoleucine-based allosteric switch controls affinity and shape shifting in integrin CD11b A-domain. J Biol Chem. 2000;275: 38762-38767.[Abstract/Free Full Text]

  43. Kallen J, Welzenbach K, Ramage P, et al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol. 1999;292: 1-9.[CrossRef][Medline] [Order article via Infotrieve]

  44. Vinogradova O, Velyvis A, Velyviene A, et al. A structural mechanism of integrin alphaIIb beta3 "inside-out" activation as regulated by its cytoplasmic face. Cell. 2002;110: 587-597.[CrossRef][Medline] [Order article via Infotrieve]

  45. Armulik A, Nilsson I, von Heijne G, Johansson S. Determination of the border between the transmembrane and cytoplasmic domains of human integrin subunits. J Biol Chem. 1999;274: 37030-37034.[Abstract/Free Full Text]

  46. Gottschalk KE, Adams PD, Brunger AT, Kessler H. Transmembrane signal transduction of the alpha(IIb)beta(3) integrin. Protein Sci. 2002;11: 1800-1812.[Abstract/Free Full Text]

  47. Humphries MJ. Integrin structure. Biochem Soc Trans. 2000;28: 311-339.[Medline] [Order article via Infotrieve]

  48. Wilkins JA, Li A, Ni H, Stupack DG, Shen C. Control of beta1 integrin function. Localization of stimulatory epitopes. J Biol Chem. 1996;271: 3046-3051.[Abstract/Free Full Text]

  49. Luque A, Gomez M, Puzon W, Takada Y, Sanchez-Madrid F, Cabanas C. Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. J Biol Chem. 1996;271: 11067-11075.[Abstract/Free Full Text]

  50. Puzon-McLaughlin W, Takada Y. Critical residues for ligand binding in an I domain-like structure of the integrin b1 subunit. J Biol Chem. 1996;271: 20438-20443.[Abstract/Free Full Text]

  51. Huang C, Zang Q, Takagi J, Springer TA. Structural and functional studies with antibodies to the integrin beta2 subunit. A model for the I-like domain. J Biol Chem. 2000;275: 21514-21524.[Abstract/Free Full Text]

  52. Kashiwagi H, Tomiyama Y, Tadokoro S, et al. A mutation in the extracellular cysteine-rich repeat region of the beta3 subunit activates integrins alphaIIb beta3 and alphaV beta3. Blood. 1999;93: 2559-2568.[Abstract/Free Full Text]

  53. Ambo H, Kamata T, Handa M, et al. Three novel integrin beta3 subunit missense mutations (H280P, C560F, and G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients. Biochem Biophys Res Commun. 1998;251: 763-768.[CrossRef][Medline] [Order article via Infotrieve]

  54. Chen P, Melchior C, Brons NH, Schlegel N, Caen J, Kieffer N. Probing conformational changes in the I-like domain and the cysteine-rich repeat of human beta3 integrins following disulfide bond disruption by cysteine mutations: identification of cysteine 598 involved in alphaIIbbeta3 activation. J Biol Chem. 2001;276: 38628-38635.[Abstract/Free Full Text]

  55. Humphries JD, Askari JA, Zhang XP, Takada Y, Humphries MJ, Mould AP. Molecular basis of ligand recognition by integrin alpha5 beta1, II: specificity of Arg-Gly-Asp binding is determined by Trp157 of the alpha subunit. J Biol Chem. 2000;275: 20337-20345.[Abstract/Free Full Text]

  56. Calvete JJ, Henschen A, Gonzalez-Rodriguez J. Assignment of disulphide bonds in human platelet GPIIIa: a disulphide pattern for the b-subunits of the integrin family. Biochem J. 1991;274: 63-71.[Medline] [Order article via Infotrieve]

  57. Loftus JC, Plow EF, Frelinger AL 3rd, et al. Molecular cloning and chemical synthesis of a region of platelet glycoprotein IIb involved in adhesive function. Proc Natl Acad Sci U S A. 1987;84: 7114-7118.[Abstract/Free Full Text]

  58. Arnaout MA, Goodman SL, Xiong JP. Coming to grips with integrin binding to ligands. Curr Opin Cell Biol. 2002;14: 641-651.[CrossRef][Medline] [Order article via Infotrieve]

  59. Lu G. TOP: a new method for protein structure comparisons and similarity searches. J Appl. Cryst. 2000;33: 176-183.[CrossRef]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Shi, S. Y. Foo, S.-M. Tan, E. P. Mitchell, S. K. A. Law, and J. Lescar
A Structural Hypothesis for the Transition between Bent and Extended Conformations of the Leukocyte beta2 Integrins
J. Biol. Chem., October 12, 2007; 282(41): 30198 - 30206.